theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Rheumatology

Hepatology   

Questions discussed in this category


How do you approach restarting immunotherapy in a patient with metastatic melanoma who previously developed immune-mediated hepatitis (Grade 3), with liver enzymes now back to baseline levels?
Given the improvement in liver function, what factors should be considered before reinitiating immunotherapy?"
4 Answers available
23480


Papers discussed in this category


Cancer chemotherapy and pharmacology, 2019 Aug 23
Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer.

Related Topics in Rheumatology

  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancers
  • Hematologic Malignancies
  • Radiation Oncology
  • Gynecologic Oncology
  • Palliation
  • Neuro-Oncology
  • Gastrointestinal Cancers
  • Genitourinary Cancers

Copyright © 2025 theMednet
All Rights Reserved.